CommercialCoverageMedium impact
08.02.13a, Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; Elevidys®)
Independence Blue Cross·Neurology, Pediatrics·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
This is a reissued policy for Elevidys® (delandistrogene moxeparvovec-rokl), a gene therapy for Duchenne muscular dystrophy. The policy has been updated with an effective date of May 28, 2025, but specific content changes are not detailed in the summary provided.
Action Required
By May 28, 2025: Billing team should review the full updated policy at the provided URL to understand specific coverage criteria and billing requirements for Elevidys gene therapy. Contact payer representatives if clarification is needed on prior authorization or documentation requirements for this specialty medication.